Explor Asthma Allergy EAA Exploration of Asthma & Allergy 2837-5076 Open Exploration Publishing 10.37349/eaa.2023.00011 100911 Review Can we apply biomarkers in the management of non-steroidal anti-inflammatory drug exacerbated respiratory disease? https://orcid.org/0000-0003-0905-4649 Rhyou Hyo-In 1 https://orcid.org/0000-0001-8759-2982 Nam Young-Hee 2 * https://orcid.org/0000-0003-2614-0303 Park Hae-Sim 3 * Guida Giuseppe Academic Editor University of Torino, Italy 1Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan 48108, Korea 2Department of Internal Medicine, Dong-A University College of Medicine, Busan 49201, Korea 3Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon 16499, Korea *Correspondence: Young-Hee Nam, Department of Internal Medicine, Dong-A University College of Medicine, 26 Daesingongwon-ro, Seo-Gu, Busan 49201, Korea. yhnam@dau.ac.kr; Hae-Sim Park, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Gyeonggi-do, Suwon 16499, Korea. hspark@ajou.ac.kr 2023 24 08 2023 1 3 89 106 16 03 2023 14 06 2023 © The Author(s) 2023. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD) is characterized by adult-onset asthma, chronic rhinosinusitis with nasal polyps (CRSwNPs), and aspirin/NSAID hypersensitivity, presenting recurrent asthma exacerbation and poor clinical outcomes. Patients with NERD have heterogeneous clinical phenotypes/endotypes, and the management of NERD remains challenging. Dysregulation of arachidonic acid (AA) metabolism and persistent eosinophilic airway inflammation are the major pathogenic mechanisms in the upper and lower airways of NERD. To date, increased levels of urinary leukotriene E4 (uLTE4) [a terminal metabolite of the lipoxygenase (LOX) pathway] have been the most relevant biomarker for NERD. It is demonstrated that mast cells, platelets, and epithelial cells can amplify upper and lower airway inflammation in NERD, and several potential biomarkers based on these complicated and heterogeneous mechanisms have been suggested. This review summarizes potential biomarkers for application in the management of NERD.

 Asthma aspirin-induced biomarkers cysteinyl leukotriene eosinophils epithelial cells mast cells platelet activation Introduction

Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD), a distinct phenotype of asthma, is defined by chronic eosinophilic inflammation of the upper and lower airways and is accompanied by asthma, chronic rhinosinusitis with nasal polyps (CRSwNPs), and hypersensitivity to aspirin/NSAID [1]. In a recent population study, the general prevalence of NERD was 1.4%, and the prevalence of NERD among patients with asthma was 6.9% [2]. Considering that more severe asthmatic symptoms and a higher prevalence of chronic rhinosinusitis (CRS) were reported in patients with NERD than in those with aspirin-tolerant asthma (ATA), the prevalence of NERD was reported to be 14.9% in patients with severe asthma [3]. Therefore, optimal management of NERD is required; however, it is still challenging. In addition, the clinical features of NERD are very diverse, and the classification of subgroups (phenotype/endotype) has not been clarified. Much effort has been made to explore relevant biomarkers based on the pathogenic mechanism of NERD; however, there are few validated biomarkers to date. The current management of NERD is not much different from that of ATA. Therefore, the novel and potential biomarkers that may be applicable in clinical practice to achieve better control of NERD are summarized in this review.

 Pathogenic mechanisms and clinical characteristics of NERD Key pathogenic mechanisms of NERD

Chronic eosinophilic inflammation and dysregulation of arachidonic acid (AA) metabolism are key pathogenic mechanisms of NERD (Figure 1) [1]. AA, a major component of cell membrane lipids, plays a central role in inflammation and the immune system through numerous bioactive metabolites. AA is metabolized by two major pathways, cyclooxygenase (COX) and lipoxygenase (LOX), where leukotriene E4 (LTE4) is the terminal metabolite of the LOX pathway among three cysteinyl LTs (CysLTs) [4]. Dysregulation of the COX and LOX pathways is noted in patients with NERD, and increased production of CysLTs induces upper and lower airway inflammation (nasal congestion, mucus production, and inflammatory cell recruitment) through CysLT receptors (CysLTRs), whereas decreased production of prostaglandin E2 (PGE2; having anti-inflammatory actions) increases the LOX pathway. Additionally, increased PGD2 and thromboxane A2 (TXA2; from the COX pathway) can activate various immune cells, contributing to the development of NERD [5]. Under these conditions, the administration of COX-1 inhibitors (NSAID) amplifies the imbalances of metabolites from the COX to LOX pathways, exacerbating upper and lower respiratory symptoms in patients with NERD [1, 5].

AA metabolism and therapeutic approach to NERD. AA metabolism is divided into two (COX and LOX) pathways. The LOX pathway is initiated by 5-LOX, which generates LTA4. LTA4 is converted to LTC4 by LTC4 synthase, then, metabolized in the order of LTD4 and LTE4. LTC4, LTD4, and LTE4 are bioactive proinflammatory mediators and are known as CysLTs. The COX pathway is initiated by COX-1 and COX-2, and AA is converted to PGH2 and subsequently further metabolized into PGI2, PGF2, PGD2, PGE2, and TXA2 by each specific synthase. Overproduction of CysLTs and increase of PGD2 and TXA2 accompanied by the decrease of PGE2 are major characteristics of NERD. Exposure to COX-1 inhibitor induces a remarkable reduction of PGE2 production and excessive CysLT production, resulting in immediate hypersensitivity reactions to NERD. DP1: D-prostanoid 1; TP: TX prostanoid; HPETE: hydroperoxyeicosatetraenoic acid; LTRA: LT receptor antagonist; EP1: E-prostanoid 1; Th2: T helper 2; CRTH2: chemoattractant receptor-homologous molecule expressed on Th2 cells. ↑: increased production of lipid mediators; ↓: decreased production of lipid mediators; arrow in black dots: inhibition of the action of the target; arrow in black: interaction between lipid mediators and their receptors

Note. Adapted from “Emerging biomarkers beyond leukotrienes for the management of nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease,” by Rhyou HI, Nam YH, Park HS. Allergy Asthma Immunol Res. 2022;14:153–67 (https://doi.org/10.4168/aair.2022.14.2.153). CC BY-NC 4.0.

Overproduction of CysLTs and PGD2 was associated with chronic eosinophilic inflammation in the upper and lower airway mucosa of patients with NERD (Figure 2). However, more complex and heterogeneous mechanisms of chronic eosinophilic airway inflammation have been reported [1, 5–7]. Interferon γ (IFN-γ), a Th1 cytokine, is increased in patients with NERD, stimulating eosinophils and increasing eosinophilic infiltration [6, 7]. Platelets facilitate the recruitment of granulocytes, which are involved in various inflammatory diseases. Platelet-adherent leukocytes, such as eosinophils, neutrophils, and monocytes, are increased in patients with NERD, increasing the levels of CysLTs [6, 7]. Both CysLTs and platelet-adherent leukocytes activate epithelial cells to release alarming cytokines such as interleukin 25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP). These alarming cytokines can reversely activate eosinophils and type 2 innate lymphoid cells (ILC2s) to release IL-4, IL-5, and IL-13 [5, 7]. Therefore, persistent and intense eosinophilic/type 2 inflammation is maintained by signals in several directions in NERD. These complex mechanisms, associated with the heterogeneous clinical features of patients, require variable biomarkers for the management of NERD.

Inflammatory pathway and therapeutic approach to NERD. Epithelial cells are injured by various exogenous factors including viruses, bacteria, and air pollutants, and injured epithelium releases various alarmins and cytokines. CysLTs can also activate epithelial cells, and induce the release of alarmins, IL-33, IL-25, and TSLP in NERD. These elevated levels of alarmins and cytokines from epithelial cells activate ILC2, eosinophils, and mast cells resulting in type 2 inflammation. Activated mast cells and eosinophils release various cytokines and chemokines, and CysLTs that can induce mucosal inflammation and bronchoconstriction. PGE2 is released from epithelial cells, fibroblasts, and leukocytes, and inhibits activation of eosinophils, mast cells, and ILC2. However, PGE2 is downregulated in NERD. Platelet-adherent leukocytes are another potent producer of CysLTs, PGD2, and TXA2, and enhance the inflammation of NERD. Airway epithelial-derived molecules including periostin, DPP10, and folliculin may affect airway remodeling, eosinophilic inflammation, and epithelium integrity and survival. DPP10: dipeptidyl peptidase 10; IgE: immunoglobulin E; P2Y12: purinergic receptor type Y, subtype 12; FcεR1: Fc epsilon receptor 1. ↑: increased production; ↓: decreased production; arrow in black: inhibition of the action of the target; arrow in blue: activation of target cells; arrow in purple: production of lipid mediators or cytokines; arrow in blue dots: inhibitory action to target cells

Note. Adapted from “Emerging biomarkers beyond leukotrienes for the management of nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease,” by Rhyou HI, Nam YH, Park HS. Allergy Asthma Immunol Res. 2022;14:153–67 (https://doi.org/10.4168/aair.2022.14.2.153). CC BY-NC 4.0.

 Clinical characteristics and heterogeneity of phenotypes in NERD

NERD is generally diagnosed between the ages of 30 and 40 years and is more commonly found in women. Most patients with NERD have reported upper airway symptoms at diagnosis, and after several years, asthma may appear, followed by NSAID hypersensitivity. Patients with NERD have more severe upper airway symptoms, including nasal blockage, stuffiness, and post-nasal drip, associated with nasal polyps (NPs) [8]. Loss of smell is also more frequently reported in patients with NERD than in those with ATA [1, 9]. In addition, patients with NERD reported frequent recurrence of CRS/NPs after surgery and underwent revision surgeries compared with ATA [1, 9, 10].

Although patients with NERD present with a wide range of asthma severities, most of them present with moderate to severe asthma [1, 3]. A meta-analysis reported that patients with NERD had a higher risk of uncontrolled asthma and higher rates of asthma exacerbation, emergency room visits, and hospitalization than those with ATA [11]. However, in a study identifying sub-phenotypes in the NERD cohort, patients with severe upper and lower airway diseases were divided differently [12]. Both shared and individual mechanisms between upper and lower airway inflammation may be present in NERD. A latent class analysis of clinical data from 201 patients with NERD based on a Polish population demonstrated four subtypes of NERD—class 1: moderate asthma, severe CRS, and blood eosinophilia; class 2: mild asthma, relatively well controlled; class 3: severe asthma with severe asthma exacerbations and airway obstruction; and class 4: poorly controlled asthma with frequent asthma exacerbations in female subjects [12]. Blood eosinophilia and increased urinary LTE4 (uLTE4) were characterized as class 1, which was associated with severe upper airway inflammation [12]. Four distinct subtypes were identified in 302 patients with NERD based on a Korean population—class 1: NERD with CRS/atopy and no urticaria; class 2: NERD with CRS and no urticaria; class 3: NERD without CRS/urticaria; and class 4: NERD with urticaria [13]. There were significant differences in the female proportion, asthma severity, sputum/blood eosinophil counts, and serum total IgE levels. Significantly higher levels of uLTE4 were noted in classes 1 and 3, suggesting that blood eosinophilia and uLTE4 are reliable biomarkers of NERD in these two studies [12, 13].

 Biomarkers for NERD: from classic to novel LTs and prostanoids Increased CysLTs

AA is catalyzed to LTA4 by 5-LOX, and unstable LTA4 is converted to LTC4 by LTC4 synthase in mast cells, macrophages, eosinophils, and basophils. The released LTC4 undergoes rapid extracellular metabolism to LTC4, LTD4, and LTE4 [14]. Increased levels of LTE4 in various samples (urine, sputum, saliva, and blood) were noted in patients with NERD compared to ATA [15–18], indicating that LTE4 is a useful biomarker for diagnosis, with proven significance and ease of sampling [18]. The ratio of LTE4 to PGF2α (PGE2 metabolite) was reported to have a more accurate diagnostic value than LTE4 [16], and is expected to be a new diagnostic biomarker for NERD. LTE4 levels in urine were further increased after aspirin challenge in patients with NERD, were associated with more severe asthmatic symptoms during aspirin challenges [15, 17, 19], and were negatively correlated with changes in forced expiratory volume in 1 s (FEV1) during aspirin desensitization (AD) [19]. In addition, uLTE4 has been used as a biomarker for response to zileuton [20], omalizumab [21], mepolizumab [22], dupilumab [23], and prasugrel (inhibiting platelet-leukocyte aggregation by binding to the P2Y12 receptor on the platelet surface) [24] in clinical studies. These findings suggest that uLTE4 may be a useful biomarker for predicting AD tolerance, treatment response, and NERD diagnosis [15–24].

Patients with NERD had 5-fold higher LTC4 synthase-containing cell counts in bronchial biopsies after placebo challenges than those with ATA, and released additional CysLTs after lysin-aspirin challenges, but not in those with ATA [25]. Overexpression of CysLTRs in the airway mucosa has also been observed in NERD [26]. The number of nasal leukocytes expressing the CysLTR1 was higher in patients with NERD and CRS than in those with ATA and was significantly decreased after desensitization with topical lysine. Overexpression of LTC4 synthase and CysLTR1 can explain the enhanced role of CysLTs, which are therapeutic targets for NERD. Taken together, uLTE4 is the most reliable diagnostic and therapeutic marker of NERD.

 Decreased PGE2

PGH2, which is metabolized from AA by COX-1 and COX-2, is converted into PGE2 by PGE2 synthase. The physiological action of PGE2 is mediated by four different G protein-coupled receptors (GPRs), EP1 to EP4 [27]. PGE2 deficiency and decreased expression of the EP2 receptor have been reported in NERD. Patients with NERD show decreased production of PGE2 in epithelial cells from NPs [28], bronchial fibroblasts [29], and peripheral blood leukocytes [30]. Hypermethylation of the PGE2 synthase gene in NPs was detected in patients with NERD compared to NPs with aspirin tolerance [31]. Expression of the EP2 receptor was lower in NP fibroblasts in patients with NERD than in those with ATA and healthy controls [32]. Inhaled PGE2 could prevent bronchoconstriction in response to aspirin challenge and excretion of uLTE4 in patients with NERD [33]. PGE2 can suppress CysLT synthesis in mast cells and aspirin/NSAID-induced activation of eosinophils in patients with NERD, but not in those with ATA or healthy controls [34, 35]. An experimental study reported that PGE2 suppressed IL-5 and IL-13 production and proliferation of ILC2 mediated by EP2 and EP4 receptors [36], and a selective EP2 agonist suppressed the release of CysLTs [35]. Taken together, PGE2 can inhibit the activation of mast cells, eosinophils, and ILC2, suppressing CysLT and type 2 cytokine production. Restoration of PGE2 and EP2 receptors is a potential therapeutic target for NERD.

 Increased PGD2

PGD2 induces bronchoconstriction and chemoattraction of eosinophils, basophils, Th2 cells, and ILC2 cells through three receptors: DP1, DP2 (called CRTH2), and TP receptors. Basal levels of PGD2 and its metabolites in the blood, urine, sputum, and NP tissue were higher in patients with NERD than in those with ATA [37–39]. Urinary PGD2 levels were correlated with a decrease in FEV1 during AD [19]. Elevated PGD2 levels can predict AD failure. Considering that increased PGD2 was found in NP tissue of patients with NERD compared to ATA, a recent randomized controlled trial investigated the efficacy of CRTH2 antagonists in 43 patients with CRSwNP, including 27 patients with NERD [40]. However, no clinical efficacy of CRSwNP was observed in the subset of study patients. Taken together, increased urinary PGD2 levels may be a biomarker for the diagnosis or severity of NERD.

 Immune cells and their cytokines Increased eosinophils

Consistently, enhanced eosinophilic inflammation is a prominent feature of NERD, and activated eosinophils are the main producers of CysLTs. Blood eosinophil counts were significantly higher in patients with NERD than in those with ATA [41]. Blood eosinophilia (> 300 cells/µL) could predict NERD with an odds ratio of 1.8, and the combination of blood eosinophilia with high uLTE4 levels had 6-fold higher odds ratio for the diagnosis of NERD. Higher eosinophil counts in bronchial and NP tissues were noted in patients with NERD than in those with ATA [25, 42]; increased eosinophilic influx into nasal tissue after aspirin challenge was found in patients with NERD compared to ATA [43]. Taken together, increased blood eosinophils along with increased uLTE4 can be used as biomarkers for the diagnosis of NERD; however, tissue eosinophilia in the upper and lower airway mucosa is not a suitable biomarker because it is difficult to sample eosinophils from these tissues.

Aspirin had a direct effect on activating eosinophils to secrete eosinophil-derived neurotoxins but did not increase CysLTs in vitro [44]. However, eosinophils derived from CD34+ progenitor cells in the presence of IFN-γ significantly produced CysLTs after the aspirin challenge. When dexmedetomidine (an eosinophil suppressor [45]) was administered to patients with CRSwNP and eosinophilia, there were no significant changes in NP scores or nasal symptoms despite the elimination of blood and tissue eosinophilia [46], questing about the influence of eosinophils in CRSwNP. Taken together, eosinophilic inflammation is known to be a major driver and target for NERD, and IFN-γ may be a novel therapeutic target.

 Activated mast cells

Activated mast cells are considered important players in NERD because they release abundant proinflammatory mediators, including CysLTs, PGD2, cytokines, and histamine [1, 5, 47]. Increased mast cells were noted in bronchial biopsies and nasal fluids of patients with NERD compared to those with ATA [48, 49]. In addition, serum tryptase levels were increased after the aspirin challenge in patients with NERD, indicating mast cell activation after the aspirin challenge [50]. A subset of patients with NERD with mast cell activation exhibited a greater decrease in FEV1 after the aspirin challenge than those without mast cell activation [50]. Higher levels of PGD2 (9α,11β-PGF2) and tryptase in the blood were noted in patients with NERD than in those with ATA, which further increased after the aspirin challenge in approximately 65% of them [38]. Mast cell activation is also initiated by FcεR1 signaling, and higher levels of IgE have been noted in CRS tissues of patients with NERD than in those with ATA [47, 51, 52]. Taken together, activated mast cells and PGD2 may be diagnostic biomarkers for classifying patients with NERD and may be potential therapeutic targets for those presenting with a more severe phenotype.

 Activated platelets and ILC2

Platelets release CysLTs after adherence to neutrophils and eosinophils. Patients with NERD had higher proportions of platelet-adherent leukocytes with overexpression of LTC4 synthase in the blood than those with ATA; activated platelet-adherent leukocytes were related to uLTE4 levels and low lung function in patients with NERD [53]. In addition, the expression of p-selectin and GPIIb/IIIa on activated platelets was positively correlated with platelet-adherent leukocytes in NERD; higher levels of plasma soluble p-selectin and soluble CD40 ligand were noted in patients with NERD than in those with ATA [54]. Therefore, activated platelet-adherent leukocytes may predict disease severity and serve as potential therapeutic targets for NERD. However, prasugrel could suppress aspirin-induced nasal symptoms and uLTE4/PGD2 production in a small subgroup of patients with NERD [24], questioning the pathogenic role of platelet-adherent leukocytes. Taken together, further investigations are needed to evaluate the diagnostic or therapeutic value of platelet-adherent leukocytes.

Moreover, activated lung-resident ILC2 by alarmin cytokines and lipid mediators contributed to type-2 inflammation by releasing IL-4, IL-5, and IL-13 [1, 5, 55, 56]. ILC2 numbers in the nasal mucosa increased during aspirin/NSAID challenges, which was associated with nasal symptoms in some patients with NERD [57]. Considering that alarmins could sequentially activate type 2 cells, including mast cells and eosinophils, a therapeutic approach to activated ILC2 will be an effective strategy for NERD.

 Epithelium-derived alarmins, cytokines, and mediators Alarmins

CysLTs and prostanoids activated airway epithelial cells (AECs) to release alarmin cytokines such as IL-25, IL-33, and TSLP [1, 5]. Plasma IL-25 levels were higher in patients with NERD than in those with ATA, which was positively correlated with a decrease in FEV1 during aspirin challenges [58]. Steroid treatment could suppress IL-33 levels in CRS tissue but did not change eosinophils in CRS tissue and fractional exhaled nitric oxide levels, suggesting that IL-33 may not be associated with type 2/eosinophilic inflammation [59]. TSLP messenger RNA (mRNA) expression in NPs was significantly correlated with the expression of PGD2 synthase, carboxypeptidase (a mast cell-specific marker), and urinary levels of PGD2, but not with uLTE4 levels in patients with NERD [39]. TSLP can induce PGD2 release from mast cells in vitro and activate eosinophils [39]. Recent clinical trials on severe type 2 asthma demonstrated the significant efficacy of tezepelumab [a monoclonal antibody (mAb) to TSLP] on symptom control and lower lung function [60, 61]. Taken together, TSLP may be a potential therapeutic target for patients with NERD with mast cell activation or higher levels of PGD2, although further investigations are needed to evaluate the role of IL-25.

 Cytokines and mediators

Periostin and transforming growth factor β1 (TGF-β1) released from activated AECs play pivotal roles in type-2 airway inflammation and remodeling in asthma [62, 63]. Higher levels of serum periostin, positively correlated with blood eosinophil counts and CRS severity, could distinguish patients with NERD from those with ATA [64]. In addition, higher levels of serum TGF-β1 were noted in patients with NERD than in those with ATA, with a positive correlation with uLTE4 levels, and TGF-β1 treatment increased eosinophils and LTE4 levels in the lung tissue in vivo [65]. These findings suggest that both periostin and TGF-β1 may be novel therapeutic targets to improve lung function and eosinophilic inflammation and to prevent airway remodeling in NERD [64, 65].

DPP10 is expressed in AECs and is associated with the development and severity of asthma [66–68]. A single nucleotide polymorphism (rs17048175) of DPP10 was significantly associated with the phenotype of NERD and was positively correlated with enhanced expression of DPP10 in patients with NERD than in those with ATA [69]. Increased levels of serum DPP10 were noted in patients with NERD compared to ATA, with a positive correlation with serum levels of TGF-β1 but a negative correlation with FEV1 [70]. These findings suggest that serum DPP10 level is a potential biomarker for the diagnosis and severity of NERD [69, 70].

Surfactant protein D, which is mainly produced from AECs, regulates airway inflammation by inhibiting mast cells and eosinophils [71]. Severe asthma is related to surfactant protein D deficiency in the airway, and it has been suggested as a useful biomarker for predicting severe asthma [72]. Compared to patients with ATA, patients with NERD had lower levels of serum surfactant protein D, and these levels were negatively correlated with a decrease in FEV1 after the lysin-aspirin challenge. In vitro study demonstrated that surfactant protein D could suppress eosinophilic airway remodeling [71], suggesting that this may be a novel therapeutic target to control AEC-mediated type 2 airway inflammation in NERD, although further elucidation is needed.

Folliculin, which is mainly expressed in AECs, is a negative regulator of cell-cell adhesion. Folliculin can affect airway epithelial integrity and survival [73, 74]. Serum folliculin levels were significantly higher in patients with NERD than in those with ATA [75]. Folliculin production increased after LTE4 treatment, followed by disruption of the tight junctions of AECs, suggesting that serum folliculin may be a potential serum biomarker for NERD. Taken together, we suggest that three AEC-derived serum biomarkers (periostin, DPP10, and folliculin) and serum surfactant protein D are potential therapeutic targets for NERD.

 Management of NERD with applying biomarkers

Traditional approaches to patients with NERD consist of pharmacological treatment and AD for asthma and CRS (with/without NPs), as well as absolute avoidance of aspirin/NSAID [1, 5]. Most patients with NERD show hypersensitivity to cross-reactive NSAID; alternative drugs must be confirmed by drug provocation tests. Pharmacological treatment of asthma (including inhaled corticosteroids plus long-acting beta-2 agonists with/without additional LT modifiers) and CRS (intranasal corticosteroids) in patients with NERD are similar to those with ATA. Although some patients can be controlled by conventional anti-inflammatory medications, patients with severe or uncontrolled asthma require additional controllers, including biologics, in which biomarkers may be applied considering the heterogeneity in the phenotypes/endotypes of NERD. AD is performed in some patients if indicated.

AD

AD is indicated in patients with NERD who require antiplatelet treatment (e.g., cardiovascular disease and antiphospholipid syndrome), chronic anti-inflammatory treatment (rheumatologic diseases), or severe CRSwNP [76]. AD proceeds with gradually increasing doses of aspirin until reaching a substantial dose range (300–650 mg per day), has been reported to improve asthma and CRS symptoms and reduce the recurrence of NPs, frequency of revision surgery, and requirements of intranasal corticosteroids [1, 5, 77]. Adverse effects, including gastrointestinal tract bleeding, dyspepsia, and urticaria/angioedema, remain the major hurdles to long-term AD [76, 78]. Although the molecular effects of AD are not fully understood, it could reduce sputum PGD2 levels and increase sputum PGE2 levels, suggesting that the reduction of PGD2 may be the major molecular effect of AD [79].

 LT modifier

LTRAs, including montelukast and pranlukast, are commonly prescribed for patients with NERD and can improve quality of life, lung function, and symptoms of asthma and CRSwNP [1, 80, 81]. Pretreatment with LTRAs could prevent bronchospasm after the aspirin challenge, which is applied during the AD process [82, 83]. LTRAs are relatively safe, but neuropsychiatric (sleep problems or hyperactivity) and gastrointestinal adverse effects have been reported, especially in children [84, 85]. LTRAs antagonize CysLTR1; however, uLTE4 levels were not associated with the response to LTRAs [82]. A recent study demonstrated higher uLTE4 levels in patients with NERD even while maintaining LTRAs as well as inhaled corticosteroids plus long-acting bronchodilators, which were associated with blood eosinophilia and poor disease control [86]. This suggests that current LTRAs are not sufficient to suppress LTE4-mediated eosinophilic inflammation and additional controllers are required for better control. GPR99 protein, previously identified as an LTE4 receptor, may be an additional therapeutic target to suppress LTE4-mediated airway inflammation in NERD [87].

A cross-sectional questionnaire study reported a higher proportion of effectively treated patients was found in those treated with zileuton (a selective inhibitor of 5-LOX) than in those treated with LTRA [88], which prolonged the time to revision surgery in patients with NERD [89]. Zileuton, after the addition of celecoxib, markedly reduced uLTE4 levels in smokers [20]. The combination of zileuton and LTRA or celecoxib may have a synergistic effect in patients with NERD. However, it is less desirable than LTRA because of concerns regarding side effects, such as hepatotoxicity [90].

 Type 2 biologics Anti-IgE antibody

Omalizumab can neutralize IgE-mediated responses and has been prescribed to patients with severe allergic asthma, CRSwNP, and chronic spontaneous urticaria. Previous studies have demonstrated that omalizumab improved asthma/CRS symptoms, disease control, and lung function in patients with NERD [91]. Omalizumab is a fairly safe drug, but severe allergic reactions such as anaphylaxis can be occurred [92]. Biomarkers, such as LTE4, PGD2, eosinophil cationic protein (ECP), and total IgE, were used to assess the efficacy of omalizumab in NERD. Omalizumab treatment for 12 months could decrease uLTE4/urinary PGD2 levels and reduce asthma exacerbation and requirements of systemic corticosteroids, as well as symptom scores of asthma and CRS [21], where their symptoms improved within the first week in more than half of the study patients, supporting that omalizumab may stabilize mast cells. Three months of omalizumab treatment reduced uLTE4 levels and increased the tolerable dose of aspirin in AD [93]. Therefore, omalizumab is beneficial for the long-term management of NERD and pre-treatment before AD.

Omalizumab is widely used in chronic urticaria that is refractory to antihistamines [94]. Approximately 20% to 35% of patients with NERD have features of NSAID-induced blended reactions, the coexistence of NERD with NSAID-induced urticaria/angioedema, or NSAID-exacerbated cutaneous disease [95]. Omalizumab was reported to reduce PGD2 production [21] and PGD2 was associated with cutaneous symptoms during aspirin challenge in patients with NERD [19]. Omalizumab may improve both respiratory and cutaneous symptoms in patients with both NERD and NSAID-exacerbated cutaneous disease. A total of 33 patients with NERD treated with omalizumab for 6 months showed improved nasal and asthma-related symptoms regardless of atopic sensitization [96]. The clinical efficacy of omalizumab correlated with elevated levels of serum total IgE, low levels of ECP, and eosinophilia. However, there was a significant decrease in tissue eosinophil count in atopic patients with NERD. These findings suggest that uLTE4/PGD2, blood eosinophils, and serum total IgE and ECP levels are potential biomarkers for predicting responses to omalizumab in NERD [19, 21, 93, 96].

 Anti-IL-5/IL-5Rα antibody

mAb inhibiting IL-5 signaling [anti-IL-5/IL-5 receptor α (IL-5Rα)], such as mepolizumab, reslizumab, and benralizumab, have been used as potent therapeutic options for severe eosinophilic asthma and/or CRSwNP [97–99]. Most common adverse events to anti-IL-5/IL-5Rα such as nasopharyngitis, injection-site reactions, and headache were generally mild [100]. However, exacerbations of asthma were rarely reported, and it should be monitored especially in NERD patients with severe asthma. A retrospective analysis of 22 patients with NERD demonstrated that mepolizumab treatment improved sinonasal symptoms and asthma control [101]. Eighteen patients with NERD receiving mepolizumab showed a significant decrease in blood eosinophils and basophils, accompanied by higher expression of CRTH2 receptors on those cells compared to control groups [22]. PGD2 and LTE4 levels in urine and PGD2, PGF2α, and TX levels in the nasal epithelium were lower in the mepolizumab-treated group than in the control group. In addition, mepolizumab treatment induced the upregulation of tight junction transcripts and cilium organization in the nasal epithelium. IL-5 signaling may be involved in the action of epithelial and immune cells. Therefore, mAbs against IL-5/IL-5Rα can improve epithelial stability and dysregulation of AA metabolism, as well as inhibit eosinophils and basophils in NERD. However, a recent study to elucidate the efficacy of benralizumab revealed that the proportion of patients showing good responses was lower in patients with NERD than in those with ATA [102], suggesting that the mechanism of eosinophilic airway inflammation in NERD is more diverse than that of IL-5 signaling. Further efforts to identify additional targets for controlling eosinophilic inflammation are essential, especially in those showing limited responses to anti-IL-5/IL-5R antibody treatments.

 Anti-IL-4Rα antibody

Dupilumab, a mAb to IL-4Rα blocking signals of IL-4 and IL-13, has been approved for the treatment of type 2 asthma, CRSwNP, and atopic dermatitis. Dupilumab is considered as a tolerable drug, but several adverse events such as ophthalmic complications, head and neck dermatitis, and hypereosinophilia have been reported [103]. Blood eosinophil count is commonly elevated in patients with NERD, and should be monitored during dupilumab treatment. Several studies have reported the efficacy of dupilumab in NERD [23, 104, 105]. In a single-blinded trial of dupilumab in NERD, improvement in quality of life, sinonasal symptoms, and computed tomography score were noted during the study period, and decreased levels of nitric oxide, uLTE4, and serum total IgE were also reported [104]. Patients with NERD treated with dupilumab for 3 months showed remarkable improvements in olfactory function, sinonasal symptoms, and lung function [23]. Nasal PGE2 levels increased, while uLTE4 and serum/nasal IgE levels decreased after dupilumab treatment. Transcripts representing epithelial dysfunction and leukocyte chemoattraction were also downregulated in sinonasal tissue. Dupilumab may act on granulocytes, AECs, and B cells, resulting in upregulation of PGE2, downregulation of CysLTs and IgE, and improvement of the epithelial barrier. Dupilumab improved sinonasal and asthmatic symptoms and reduced asthma exacerbations in patients with NERD who failed to respond to anti-IL-5/IL-5Rα treatment [105]. Serum IgE levels were higher in patients with NERD who switched biologics from IL-5/IL-5Rα mAbs to dupilumab than in those who continued with mepolizumab (responders to mepolizumab). The most appropriate biologic treatment should be elucidated considering the heterogeneity of NERD. Elevated serum IgE may be used as a biomarker for predicting patients who have a favorable response to dupilumab treatment than to anti-IL-5/IL-5Rα antibody treatment in NERD.

 Anti-TSLP antibody

Tezepelumab is a humanized mAb to TSLP, which is an alarming cytokine of AECs that induces the activation of type 2 inflammation. In 2021, it became the first biologic to be approved for severe asthma by the Food and Drug Administration (FDA) [106], but there have been no studies on the efficacy of tezepelumab in NERD. However, epithelium-immune cell interactions are known to be a pivotal mechanism of NERD, and tezepelumab is expected to be effective in patients with NERD.

 Nanoparticles

Nanoparticles have advantages in controllable size, low cytotoxicity, and good biocompatibility. The use of nanoparticles has therapeutic efficacy by improving pharmacokinetics, reducing drug toxicities, and targeting drug delivery [107]. Therefore, the application of nanoparticles to deliver appropriate medications has been widely explored in various medical fields, particularly in malignancy [108]. Application of nanoparticles such as polymeric nanoparticles, solid lipid nanoparticles, extracellular vesicle nanomaterials, and metal nanoparticles in asthma have been also investigated for overcoming the limitation of classical therapeutic drugs and achieving precise medicine [109, 110]. Ligands targeting AECs such as adhesion molecule-1, anti-epithelial adhesion molecule, and Toll-like receptor 7 (TLR7) are used in the application of airway epithelial-targeted nanoparticles in asthma, and they may have the ability to inhibit proinflammatory response of epithelium [111]. Recently, carbon structures such as graphene and its derivatives are favorable candidates for nanoparticles in biomedicine. Electrochemical graphene-based sensors can detect nitrite in exhaled breathing condensate samples and be expected as portable airway inflammation monitors with high sensitivity and cost-effectiveness compared to traditional nitrite detection technology [112, 113].

Nanobubbles are spherical gas-containing vesicles within liquid having diameters less than 1,000 nm. Nanobubbles are favorable carriers for tissue or cell oxygenation, and oxygen-containing nanobubbles are emphasized as emerging candidates for tissue oxygenation, tissue repair, and anti-inflammatory treatment of various diseases [114, 115]. Especially, intravenous oxygen-containing nanobubbles may be a novel treatment strategy for hypoxic conditions such as acute respiratory failure and corona virus disease 2019 (COVID19) infection [116]. Diverse routes carrying oxygenated nanobubbles are also explored, and inhalation of aqueous dispersion of oxygen nanobubbles can be applied as a novel drug delivery as well as an oxygen supplier in airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) [117]. However, the application of nanotechnology in clinical practice has still challenges and further research is needed. Especially, asthma is a complex and heterogeneous disease, and further clarification of biomarkers is needed to achieve appropriate application of nanotechnology in the management of asthma or NERD.

 Conclusions

LTE4 remains the most relevant biomarker for the diagnosis of NERD. Urinary PGD2 has been suggested to be a potential mast cell marker for classifying NERD. Epithelium-derived markers, such as periostin, DPP10, and folliculin have been suggested as potential therapeutic targets and biomarkers for representing the severity of NERD. Anti-inflammatory agents, such as inhaled corticosteroids and/or LTRA, are the mainstay of management in NERD, and biologics are promising agents for controlling NERD. High serum total IgE, eosinophilia, and uLTE4 may be potential biomarkers for predicting the response to omalizumab and dupilumab. Further investigations are needed to validate the role of these biomarkers in longitudinal outcome models of NERD.

 Abbreviations AA

arachidonic acid

 AD

aspirin desensitization

 AECs

airway epithelial cells

 ATA

aspirin-tolerant asthma

 COX

cyclooxygenase

 CRS

chronic rhinosinusitis

 CRSwNPs

chronic rhinosinusitis with nasal polyps

 CRTH2

chemoattractant receptor-homologous molecule expressed on T helper 2 cells

 CysLTRs

cysteinyl leukotriene receptors

 CysLTs

cysteinyl leukotrienes

 DP1

D-prostanoid 1

 DPP10

dipeptidyl peptidase 10

 ECP

eosinophil cationic protein

 EP1

E-prostanoid 1

 FEV1

forced expiratory volume in 1 s

 IFN-γ

interferon γ

 IgE

immunoglobulin E

 IL-25

interleukin 25

 IL-5Rα

interleukin 5 receptor α

 ILC2s

type 2 innate lymphoid cells

 LOX

lipoxygenase

 LTE4

leukotriene E4

 LTRA

leukotriene receptor antagonist

 mAb

monoclonal antibody

 NERD

non-steroidal anti-inflammatory drug-exacerbated respiratory disease

 NPs

nasal polyps

 NSAID

non-steroidal anti-inflammatory drug

 PGE2

prostaglandin E2

 TGF-β1

transforming growth factor β1

 Th2

T helper 2

 TSLP

thymic stromal lymphopoietin

 TXA2

thromboxane A2

 uLTE4

urinary leukotriene E4

 Declarations Author contributions

HSP: Conceptualization, Writing—review & editing, Supervision. YHN: Writing—original draft, Writing—review & editing. HIR: Writing—original draft. All authors read and approved the submitted version.

 Conflicts of interest

The authors declare that they have no conflicts of interest.

 Ethical approval

Not applicable.

 Consent to participate

Not applicable.

 Consent to publication

Not applicable.

 Availability of data and materials

Not applicable.

 Funding

This study was supported by the Korea Health Technology R&D Project through a Korea Health Industry Development Institute (KHIDI) grant funded by the Ministry of Health and Welfare, Republic of Korea Grant No. [HR16C0001]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

 Copyright

© The Author(s) 2023.

 Kowalski ML Agache I Bavbek S Bakirtas A Blanca M Bochenek G et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)—a EAACI position paper† Allergy 2019 74 28 39 10.1111/all.1359930216468 Andersén H Ilmarinen P Honkamäki J Tuomisto LE Hisinger-Mölkänen H Backman H et al. NSAID-exacerbated respiratory disease: a population study ERJ Open Res 2022 8 00462-2021 10.1183/23120541.00462-202135083326PMC8784895 Rajan JP Wineinger NE Stevenson DD White AA Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature J Allergy Clin Immunol 2015 135 676 81.E1 10.1016/j.jaci.2014.08.02025282015 Wang B Wu L Chen J Dong L Chen C Wen Z et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets Signal Transduct Target Ther 2021 6 94 10.1038/s41392-020-00443-w33637672PMC7910446 Woo SD Luu QQ Park HS NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care Font Pharmacol 2020 11 1147 10.3389/fphar.2020.0114732848759PMC7399220 Steinke JW Wilson JM Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances J Asthma Allergy 2016 9 37 43 10.2147/JAA.S8873927022293PMC4790533 Lyly A Laidlaw TM Lundberg M Pathomechanisms of AERD—recent advances Front Allergy 2021 2 734733 10.3389/falgy.2021.73473335387030PMC8974777 Lilja MJ Koskinen A Virkkula P Vento SI Myller J Hammarén-Malmi S et al. Factors affecting the control of chronic rhinosinusitis with nasal polyps: a comparison in patients with or without NERD Allergy Rhinol 2021 12 21526567211003844 10.1177/2152656721100384433996192PMC8082978 Stevens WW Schleimer RP Aspirin-exacerbated respiratory disease as an endotype of chronic rhinosinusitis Immunol Allergy Clin North Am 2016 36 669 80 10.1016/j.iac.2016.06.00427712762PMC5119761 Yip J Yao CM Lee JM State of the art: a systematic review of the surgical management of aspirin exacerbated respiratory disease Am J Rhinol Allergy 2014 28 493 501 10.2500/ajra.2014.28.410325514486 Morales DR Guthrie B Lipworth BJ Jackson C Donnan PT Santiago VH NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity Allergy 2015 70 828 35 10.1111/all.1262925855099 Bochenek G Kuschill-Dziurda J Szafraniec K Plutecka H Szczeklik A Nizankowska-Mogilnicka E Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis J Allergy Clin Immunol 2014 133 98 103 10.1016/j.jaci.2013.07.00423993879 Lee HY Ye YM Kim SH Ban GY Kim SC Kim JH et al. Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease Allergy 2017 72 616 26 10.1111/all.1307527805264 Boyce JA Kanaoka Y Cysteinyl leukotrienes and their receptors: emerging concepts Allergy Asthma Immunol Res 2014 6 288 95 10.4168/aair.2014.6.4.28824991451PMC4077954 Gaber F Daham K Higashi A Higashi N Gülich A Delin I et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma Thorax 2008 63 1076 82 10.1136/thx.2008.10119618757457 Ban GY Cho K Kim SH Yoon MK Kim JH Lee HY et al. Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease Clin Exp Allergy 2017 47 37 47 10.1111/cea.1279727533637 Christie PE Tagari P Ford-Hutchinson AW Charlesson S Chee P Arm JP et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects Am Rev Respir Dis 1991 143 1025 9 10.1164/ajrccm/143.5_Pt_1.10251850964 Bochenek G Stachura T Szafraniec K Plutecka H Sanak M Nizankowska-Mogilnicka E et al. Diagnostic accuracy of urinary LTE4 measurement to predict aspirin-exacerbated respiratory disease in patients with asthma J Allergy Clin Immunol Pract 2018 6 528 35 10.1016/j.jaip.2017.07.00128888846 Cahill KN Bensko JC Boyce JA Laidlaw TM Prostaglandin D2: a dominant mediator of aspirin exacerbated respiratory disease J Allergy Clin Immunol 2015 135 245 52 10.1016/j.jaci.2014.07.03125218285PMC4289104 Mohebati A Milne GL Zhou XK Duffield-Lillico AJ Boyle JO Knutson A et al. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers Cancer Prev Res (Phila) 2013 6 646 55 10.1158/1940-6207.CAPR-13-008323682075PMC3707304 Hayashi H Mitsui C Nakatani E Fukutomi Y Kajiwara K Watai K et al. Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2016 137 1585 7.E4 10.1016/j.jaci.2015.09.03426559322 Buchheit KM Lewis E Gakpo D Hacker J Sohail A Taliaferro F et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2021 148 574 84 10.1016/j.jaci.2021.05.04334144111PMC9096876 Buchheit KM Sohail A Hacker J Maurer R Gakpo D Bensko JC et al. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2022 150 415 24 10.1016/j.jaci.2022.04.00735460728PMC9378638 Laidlaw TM Cahill KN Cardet JC Murphy K Cui J Dioneda B et al. A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2019 143 316 24.E7 10.1016/j.jaci.2018.06.00129890239PMC6286686 Cowburn AS Sladek K Soja J Adamek L Nizankowska E Szczeklik A et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma J Clin Invest 1998 101 834 46 10.1172/JCI6209466979PMC508632 Rousa AR Parikh A Scadding G Corrigan CJ Lee TH Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis N Engl J Med 2002 347 1493 9 10.1056/NEJMoa01350812421891 Rusznak M Peebles RS Jr Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells Curr Opin Allergy Clin Immunol 2019 19 38 45 10.1097/ACI.000000000000049830516547PMC6296891 Kowalski ML Pawliczak R Wozniak J Siuda K Poniatowska M Iwaszkiewicz J et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients Am J Respir Crit Care Med 2000 161 391 8 10.1164/ajrccm.161.2.990203410673176 Pierzchalska M Szabó Z Sanak M Soja J Szczeklik A Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma J Allergy Clin Immunol 2003 111 1041 8 10.1067/mai.2003.149112743569 Jedrzejczak-Czechowicz M Lewandowska-Polak A Bienkiewicz B Kowalski ML Involvement of 15-lipoxygenase and prostaglandin EP receptors in aspirin triggered 15-hydroxyeicosatetraenoic acid generation in aspirin-sensitive asthmatics Clin Exp Allergy 2008 38 1108 16 10.1111/j.1365-2222.2008.02989.x18462455 Cheong HS Park SM Kim MO Park JS Lee JY Byun JY et al. Genome-wide methylation profile of nasal polyps: relation to aspirin hypersensitivity in asthmatics Allergy 2011 66 637 44 10.1111/j.1398-9995.2010.02514.x21121930 Cahill KN Raby BA Zhou X Guo F Thibault D Baccarelli A et al. Impaired E prostanoid2 expression and resistance to prostaglandin E2 in nasal polyp fibroblasts from subjects with aspirin-exacerbated respiratory disease Am J Respir Cell Mol Biol 2016 54 34 40 10.1165/rcmb.2014-0486OC26051534PMC4742927 Sestini P Armetti L Gambaro G Pieroni MG Refini RM Sala A et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma Am J Respir Crit Care Med 1996 153 572 5 10.1164/ajrccm.153.2.85641008564100 Wang XS Wu AY Leung PS Lau HYA PGE2 suppresses excessive anti-IgE induced cysteinyl leukotrienes production in mast cells of patients with aspirin exacerbated respiratory disease Allergy 2007 62 620 7 10.1111/j.1398-9995.2007.01364.x17508965 Pal K Ramsden M Shim YM Borish L Payne SC Steinke JW Suppression of aspirin-mediated eosinophil activation by prostaglandin E2: relevance to aspirin/NSAID hypersensitivity Ann Allergy Asthma Immunol 2019 123 503 6 10.1016/j.anai.2019.09.00331513909PMC6825585 Maric J Ravindran A Mazzurana L Björklund AK Acker AV Rao A et al. Prostaglandin E2 suppresses human group 2 innate lymphoid cell function J Allergy Clin Immunol 2018 141 1761 73.E6 10.1016/j.jaci.2017.09.05029217133PMC5929462 Mastalerz L Celejewska-Wójcik N Wójcik K Gielicz A Januszek R Cholewa A et al. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity Allergy 2014 69 1550 9 10.1111/all.1251225123806 Bochenek G Nagraba K Nizankowska E Szczeklik A A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge J Allergy Clin Immunol 2003 111 743 9 10.1067/mai.2003.138712704352 Buchheit KM Cahill KN Katz HR Murphy KC Feng C Lee-Sarwar K et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2016 137 1566 76.E5 10.1016/j.jaci.2015.10.02026691435PMC4860132 Price CPE Guo A Stevens WW Cousens L Vu THT Suh LA et al. Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: a randomized controlled clinical trial Clin Exp Allergy 2022 52:859 967 10.1111/cea.1415835524339 Comhair SAA Bochenek G Baicker-McKee S Wang Z Stachura T Sanak M et al. The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease Respir Res 2018 19 210 10.1186/s12931-018-0909-630376852PMC6208044 Payne SC Early SB Huyett P Han JK Borish L Steinke JW Evidence for distinct histologic profile of nasal polyps with and without eosinophilia† Laryngoscope 2011 121 2262 7 10.1002/lary.2196921898422PMC3183261 Kupczyk M Kurmanowska Z Kupryś-Lipińska I Bocheńska-Marciniak M Kuna P Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge Respir Med 2010 104 1404 9 10.1016/j.rmed.2010.04.01720452758 Steinke JW Negri J Liu L Payne SC Borish L Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease J Immunol 2014 193 41 7 10.4049/jimmunol.130175324890720PMC4065844 Dworetzky SI Hebrank GT Archibald DG Reynolds IJ Farwell W Bozik ME The targeted eosinophil-lowering effects of dexpramipexole in clinical studies Blood Cells Mol Dis 2017 63 62 5 10.1016/j.bcmd.2017.01.00828178599 Laidlaw TM Prussin C Panettieri RA Lee S Ferguson BJ Adappa ND et al. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size Laryngoscope 2019 129 E61 6 10.1002/lary.2756430284267 Kuruvilla ME Vanijcharoenkarn K Levy JM The role of mast cells in aspirin-exacerbated respiratory disease (AERD) pathogenesis: implications for future therapeutics J Asthma Allergy 2020 13 463 70 10.2147/JAA.S23746333116654PMC7569245 Nasser SM Pfister R Christie PE Sousa AR Barker J Schmitz-Schumann M et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects Am J Respir Crit Care Med 1996 153 90 6 10.1164/ajrccm.153.1.85421688542168 Takahashi T Kato A Berdnikovs S Stevens WW Suh LA Norton JE et al. Microparticles in nasal lavage fluids in chronic rhinosinusitis: potential biomarkers for diagnosis of aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2017 140 720 9 10.1016/j.jaci.2017.01.02228238741PMC5568994 Cahill KN Murphy K Singer J Israel E Boyce JA Laidlaw TM Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2019 143 799 803.E3 10.1016/j.jaci.2018.10.00730339852PMC6519056 Johns CB Laidlaw TM Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease Am J Rhinol Allergy 2014 28 287 9 10.2500/ajra.2014.28.405425197914 Buchheit KM Dwyer DF Ordovas-Montanes J Katz HR Lewis E Vukovic M et al. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2020 145 1574 84 10.1016/j.jaci.2020.02.03532199912PMC7282948 Laidlaw TM Kidder MS Bhattacharyya N Xing W Shen S Milne GL et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes Blood 2012 119 3790 8 10.1182/blood-2011-10-38482622262771PMC3335383 Mitsui C Kajiwara K Hayashi H Ito J Mita H Ono E et al. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2016 137 400 11 10.1016/j.jaci.2015.05.04126194538 Xue L Salimi M Panse I Mjösberg JM McKenzie ANJ Spits H et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells J Allergy Clin Immunol 2014 133 1184 94 10.1016/j.jaci.2013.10.05624388011PMC3979107 Salimi M Stöger L Liu W Go S Pavord I Klenerman P et al. Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines J Allergy Clin Immunol 2017 140 1090 100.E11 10.1016/j.jaci.2016.12.95828115217PMC5624780 Eastman JJ Cavagnero KJ Deconde AS Kim AS Karta MR Broide DH et al. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease J Allergy Clin Immunol 2017 140 101 8.E3 10.1016/j.jaci.2016.11.02328279492PMC5496786 Lee JU Chang HS Lee HJ Bae DJ Son JH Park JS et al. Association of interleukin-25 levels with development of aspirin induced respiratory disease Respir Med 2017 123 71 8 10.1016/j.rmed.2016.11.02028137499 Tan LH Lin C Ungerer H Kumar A Qatanani A Adappa ND et al. Steroid affected cytokines in aspirin-exacerbated respiratory disease Int Forum Allergy Rhinol 2022 12 1232 41 10.1002/alr.2297735032094 Menzies-Gow A Corren J Bourdin A Chupp G Israel E Wechsler ME et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma N Engl J Med 2021 384 1800 9 10.1056/NEJMoa203497533979488 Menzies-Gow A Wechsler ME Brightling CE Korn S Corren J Israel E et al. DESTINATION study investigators Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study Lancet Respir Med 2023 11 425 38 Erratum in: Lancet Respir Med. 2023;11:e25. 10.1016/S2213-2600(22)00492-136702146 O’Dwyer DN Moore BB The role of periostin in lung fibrosis and airway remodeling Cell Mol Life Sci 2017 74 4305 14 10.1007/s00018-017-2649-z28918442PMC5659879 Choi YW Lee DH Lee JH Shin YS Kim SH Park HS Immunomodulatory function of surfactant protein D in eosinophilic asthma Allergy 2019 74 192 5 10.1111/all.1358830076619 Kim MA Izuhara K Ohta S Ono J Yoon MK Ban GY et al. Association of serum periostin with aspirin-exacerbated respiratory disease Ann Allergy Asthma Immunol 2014 113 314 20 10.1016/j.anai.2014.06.01425037608 Choi YW Sim SY Lee DH Lee HR Ban GY Shin YS et al. Effect of TGF-β1 on eosinophils to induce cysteinyl leukotriene E4 production in aspirin-exacerbated respiratory disease PLoS One 2021 16 e0256237 10.1371/journal.pone.025623734437574PMC8389430 Moheimani F Hsu ACY Reid AT Williams T Kicic A Stick SM et al. The genetic and epigenetic landscapes of the epithelium in asthma Respir Res 2016 17 119 10.1186/s12931-016-0434-427658857PMC5034566 Adcock IM Kirkham PA PHF11 and DPP10: a tail of two genes in asthma Respiration 2010 79 14 6 10.1159/00023597219729874 Allen M Heinzmann A Noguchi E Abecasis G Bronxholme J Ponting CP et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14 Nat Genet 2003 35 258 63 10.1038/ng125614566338 Kim SH Choi HN Yoon MG Ye YM Park HS Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease Ann Allergy Asthma Immunol 2015 114 208 13 10.1016/j.anai.2014.12.00325592153 Sim SY Choi YW Lee DH Lee HR Shin YW Park HS Contribution of dipeptidyl peptidase 10 to airway dysfunction in patients with NSAID-exacerbated respiratory disease Clin Exp Allergy 2022 52 115 26 10.1111/cea.1400334431147 Choi YW Lee DH Trinh HKT Ban GY Park HK Shin YS et al. Surfactant protein D alleviates eosinophil-mediated airway inflammation and remodeling in patients with aspirin-exacerbated respiratory disease Allergy 2019 74 78 88 10.1111/all.1345829663427 Mackay RMA Grainge CL Lau LC Barber C Clark HW Howarth PH Airway surfactant protein D deficiency in adults with severe asthma Chest 2016 149 1165 72 10.1016/j.chest.2015.11.01226836907PMC4944769 Medvetz DA Khabibullin D Hariharan V Ongusaha PP Goncharova EA Schlechter T et al. Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion PLoS One 2012 7 e47842 10.1371/journal.pone.004784223139756PMC3490959 Pham DL Trinh TH Ban GY Kim SH Park HS Epithelial folliculin is involved in airway inflammation in workers exposed to toluene diisocyanate Exp Mol Med 2017 49 e395 10.1038/emm.2017.18029147010PMC5704188 Trinh HKU Pham DL Choi YW Kim HM Kim SH Park HS Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease Clin Exp Allergy 2018 48 1464 73 10.1111/cea.1325330126026 Makowska J Makowski M Kowalski ML NSAIDs hypersensitivity: when and how to desensitize? Curr Treat Options Allergy 2015 2 124 40 10.1007/s40521-015-0049-x Stevens WW Jerschow E Baptist AP Borish L Bosso JV Buchheit KM et al. The role of AD followed by oral aspirin therapy in managing patients with apirin-exacerbated respiratory disease: a work group report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology J Allergy Clin Immunol 2021 147 827 44 10.1016/j.jaci.2020.10.04333307116PMC7980229 Esmaeilzadeh H Zare M Alyasin S Nabavizadeh H Mortazavi N Kanannejad Z A review of aspirin-exacerbated respiratory diseases and immunological efficacy of aspirin desensitization Iran J Allergy Asthma Immunol 2022 21 512 23 10.18502/ijaai.v21i5.1103936341560 Bobolea I Pozo VD Sanz V Cabaňas R Fiandor A Alfonso-Carrillo C et al. Aspirin desensitization in aspirin-exacerbated respiratory disease: new insights into the molecular mechanisms Respir Med 2018 143 39 41 10.1016/j.rmed.2018.08.00930261990 Wentzel JL Soler ZM DeYoung K Nguyen SA Lohia S Schlosser RJ Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review Am J Rhinol Allergy 2013 27 482 9 10.2500/ajra.2013.27.397624274224PMC3899527 Dahlén SE Malmström K NizankowskaE Dahlén B Kuna P Kowalski M et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist Am J Respir Crit Care Med 2002 165 9 14 10.1164/ajrccm.165.1.201008011779723 Park JS Jang AS Park SW Lee YM Uh ST Kim YH et al. Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics Allergy Asthma Immunol Res 2010 2 48 54 10.4168/aair.2010.2.1.4820224678PMC2831603 White A Ludington E Mehra P Stevenson DD Simon RA Effect of leukotriene modifier drugs on the safety of oral aspirin challenges Ann Allergy Asthma Immunol 2006 97 688 93 10.1016/S1081-1206(10)61101-517165280 Dixon EG Rugg-Gunn CE Sellick V Sinha IP Hawcutt DB et al. Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review BMJ Paediatr Open 2021 5 e001206 10.1136/bmjpo-2021-00120634712847PMC8515462 Erdem SB Nacaroglu HT Karkiner CSU Gunay I Can D et al. Side effects of leukotriene receptor antagonists in asthmatic children Iran J Pediatr 2015 25 e3313 10.5812/ijp.331326495098PMC4610338 Ban GY Kim SH Park HS Persistent eosinophilic inflammation in adult asthmatics with high serum and urine levels of leukotriene E4 J Asthma Allergy 2021 14 1219 30 10.2147/JAA.S32549934675552PMC8520485 Kanaoka Y Maekawa A Austen KF Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand* J Biol Chem 2013 288 19067 72 10.1074/jbc.C113.45370423504326PMC3630866 Ta V White AA Survey-defied patient experiences with aspirin-exacerbated respiratory disease J Allergy Clin Immunol Pract 2015 3 711 8 10.1016/j.jaip.2015.03.001 25858054 Lee SE Farquhar DR Adams KN Masood MM Senior BA Thorp BD et al. Effect of zileuton treatment on sinonasal quality of life in patients with aspirin-exacerbated respiratory disease Am J Rhinol Allergy 2019 33 791 5 10.1177/194589241987321131483687PMC6843740 Rodríguez-Jiménez JC Moreno-Paz FJ Terán LM Guaní-Guerra E Aspirin exacerbated respiratory disease: current topics and trends Respir Med 2018 135 62 75 10.1016/j.rmed.2018.01.00229414455 Taniguchi M Heffler E Olze H White A Côrte-Real J Olsson P et al. The role of omalizumab in NSAID-exacerbated respiratory disease: a narrative review J Allergy Clin Immunol Pract 2022 10 2570 8 10.1016/j.jaip.2022.06.01635764285 Kim HL Leigh R Becker A Omalizumab: practical considerations regarding the risk of anaphylaxis Allergy Asthma Clin Immunol 2010 6 32 10.1186/1710-1492-6-3221129189PMC3006370 Hayashi H Fukutomi Y Mitsui C Kajiwara K Watai K Kamide Y et al. Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial Am J Respir Crit Care Med 2020 201 1488 98 10.1164/rccm.201906-1215OC32142372PMC7301746 Yeung WYW Park HS Update on the management of nonsteroidal anti-inflammatory drug hypersensitivity Yonsei Med J 2020 61 4 14 10.3349/ymj.2020.61.1.431887794PMC6938782 Hur GY Park HS Clinical characteristics of NSAID-induced blended reaction Allergy Asthma Immunol Res 2021 13 171 2 10.4168/aair.2021.13.2.17133474853PMC7840881 Quint T Dahm V Ramazanova D Arnoldner MA Kurz H Janik S et al. Omalizumab-induced aspirin tolerance in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease patients is independent of atopic sensitization J Allergy Clin Immunol Pract 2022 10 506 16.E6 10.1016/j.jaip.2021.09.05034678497 Haldar P Brightling CE Hargadon B Gupta S Monteiro W Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 2009 360 973 84 Erratum in: N Engl J Med. 2011;364:588. 10.1056/NEJMoa080899119264686PMC3992367 Gevaert P Bruaene NV Cattaert T Steen KV Zele TV Acke F et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis J Allergy Clin Immunol 2011 128 989 95.E8 10.1016/j.jaci.2011.07.05621958585 Weinstein SF Katial RK Bardin P Korn S McDonald M Garin M et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps J Allergy Clin Immunol Pract 2019 7 589 96.E3 10.1016/j.jaip.2018.08.02130193936 Bagnasco D Ferrando M Varricchi G Puggioni F Passalacqua G Canonica GW Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilia asthma Front Med (Lausanne) 2017 4 135 10.3389/fmed.2017.0013528913336PMC5583162 Tuttle KL Buchheit KM Laidlaw TM Cahill KN A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease J Allergy Clin Immunol Pract 2018 6 1045 7 10.1016/j.jaip.2018.01.03829501519PMC5997393 Numata T Miyagawa H Nishioka S Okuda K Utsumi H Hashimoto M et al. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study BMC Pulm Med 2020 20 207 10.1186/s12890-020-01248-x32746787PMC7398222 Kychygina A Cassagne M Tauber M Galiacy S Paul C Fournié P et al. Dupilumab-associated adverse events during treatment of allergic diseases Clin Rev Allergy Immunol 2022 62 519 33 10.1007/s12016-022-08934-035275334 Mustafa SS Vadamalai K Scott B Ramsey A Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease Am J Rhinol Allergy 2021 35 399 407 10.1177/194589242096196932967430 Bavaro N Gakpo D Mittal A Bensko JC Laidlaw TM Buchheit KM Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting J Allergy Clin Immunol Pract 2021 9 2910 2 10.1016/j.jaip.2021.02.02033631410PMC8277677 Hoy SM Tezepelumab: first approval Drugs 2022 82 461 8 10.1007/s40265-022-01679-235184265 Patra JK Das G Fraceto LF Campos EVR Rodriguez-Torres MDP Acosta-Torres LS et al. Nano based drug delivery systems: recent developments and future prospects J Nanobiotechnology 2018 16 71 10.1186/s12951-018-0392-830231877PMC6145203 Mitchell MJ Billingsley MM Haley RM Wechsler ME Peppas NA Langer R Engineering precision nanoparticles for drug delivery Nat Rev Drug Discov 2021 20 101 24 10.1038/s41573-020-0090-833277608PMC7717100 Zuo X Guo X Gu Y Zheng H Zhou Z Wang X et al. Recent advances in nanomaterials for asthma treatment Int J Mol Sci 2022 23 14427 10.3390/ijms23221442736430906PMC9696023 Cheng WC Chen CH Nanotechnology bring a new hope for asthmatics Ann Transl Med 2019 7 516 10.21037/atm.2019.09.15331807498PMC6861745 Kan S Hariyadi DM Grainge C Knight DA Bartlett NW Kiang M et al. Airway epithelial-targeted nanoparticles for asthma therapy Am J Physiol Lung Cell Mol Physiol 2020 318 L500 9 10.1152/ajplung.00237.201931913649 Gholizadeh A Black K Kipen H Laumbach R Gow A Weisel C et al. Detection of respiratory inflammation biomarkers in non-processed exhaled breath condensate samples using reduced graphene oxide RSC Adv 2022 12 35627 38 10.1039/d2ra05764f36545081PMC9745889 Gholizadeh A Voiry D Weisel C Gow A Laumbach R Kipen H et al. Toward point-of-care management of chronic respiratory conditions: electrochemical sensing of nitrite content in exhaled breath condensate using refused graphene oxide Microsyst Nanoeng 2017 3 17022 10.1038/micronano.2017.2231057865PMC6444995 Atkinson AJ Apul OG Schneider O Garcia-Segura S Westerhoff P Nanobubble technologies offer opportunities to improve water treatment Acc Chem Res 2019 52 1196 205 10.1021/acs.accounts.8b0060630958672 Jin J Yang L Chen F Gu N Drug delivery system based on nanobubbles Interdiscip Mater 2022 1 471 94 10.1002/idm2.12050 Afshari R Akhavan O Hamblin MR Varma RS Review of oxygenation with nanobubbles: possible treatment for hypoxic COVID-19 patients ACS Appl Nano Mater 2021 4 11386 412 10.1021/acsanm.1c01907 37556289 PMC8565459 Odziomek M Ulatowski K Dobrowolska K Górniak I Sobieszuk P Sosnowski TR Aqueous dispersions of oxygen nanobubbles for potential application in inhalation therapy Sci Rep 2022 12 12455 10.1038/s41598-022-16720-3 35864438 PMC9302230